Skip to main content
SpringerLink
Log in

Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes

  • Original Article
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the long-term cost-effectiveness of transferring type 2 diabetes patients to an insulin detemir regimen after failure to achieve adequate control with oral antidiabetic agents (OADs) alone, or in combination with neutral protamine hagedorn (NPH) insulin, or with insulin glargine in Germany.

Methods

A computer simulation model of diabetes was used to make long-term projections of future clinical outcomes and direct medical costs based on findings from a German subanalysis of the PREDICTIVE trial. The study analysed the impact of converting patients failing their current treatments to an insulin detemir regimen. Therapy conversion to insulin detemir ± OADs was associated with a significant reduction in glycosylated haemoglobin (HbA1c) compared with OADs alone, NPH insulin ± OADs, and insulin glargine ± OADs. Across all three groups, hypoglycaemia rates decreased by 80% and patients lost an average of 0.9 kg of body weight during treatment with insulin detemir ± OADs.

Results

Therapy conversion to insulin detemir ± OADs was projected to improve life expectancy by 0.28 years compared with OADs alone, and by 0.13 years compared with the NPH and glargine regimens. Transfer to insulin detemir was associated with improvements in quality-adjusted life expectancy of 0.21 quality-adjusted life years (QALYs) over OADs alone, 0.28 QALYs over NPH ± OADs, and 0.29 QALYs over glargine ± OADs. Insulin detemir was associated with savings over patient lifetimes due to reduced diabetes-related complications in all three comparisons.

Conclusions

Therapy conversion to insulin detemir ± OADs in type 2 diabetes patients failing OADs alone, NPH or insulin glargine regimens was associated with improvements in life expectancy, quality-adjusted life expectancy and cost savings in all three scenarios evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Liebl A. Costs involved in the early and late phases of diabetes mellitus [in German]. Internist (Berl). 2007;48:708–714.

    Article  CAS  Google Scholar 

  2. Liebl A, Spannheimer A, Reitberger U, Gortz A. Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 study [in German]. Med Klin (Munich). 2002;97:713–719.

    Article  Google Scholar 

  3. Koster I, Hauner H, von FL. Heterogeneity of costs of diabetic patients: the Cost of Diabetes Mellitus study [in German]. Dtsch Med Wochenschr. 2006;131:804–810.

    Article  PubMed  CAS  Google Scholar 

  4. The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.

    Article  Google Scholar 

  5. The UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.

    Article  Google Scholar 

  6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412.

    Article  PubMed  CAS  Google Scholar 

  7. Schneider CA, Herold G, Gysan D, Albus C, Bjarnason-Wehrens B, Predel HG. Prevalence of cardiovascular risk factors in middle-aged type 2 diabetic automobile employees assessed at the workplace — the Praeford study. J Occup Environ Med. 2007;49:481–483.

    Article  PubMed  Google Scholar 

  8. Pittrow D, Stalla GK, Zeiher AM, et al. Prevalence, drug treatment and metabolic control of diabetes mellitus in primary care [in German]. Med Klin (Munich). 2006;101:635–644.

    Article  CAS  Google Scholar 

  9. Yurgin N, Secnik K, Lage MJ. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. Clin Ther. 2007;29:316–325.

    Article  PubMed  CAS  Google Scholar 

  10. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28:1569–1581.

    Article  PubMed  CAS  Google Scholar 

  11. Abraham C, Priest L. Crisis in cataract surgery epitomizes waiting-list woes. Globe and Mail. 11 September 2004.

  12. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-totarget trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269–1274.

    Article  PubMed  CAS  Google Scholar 

  13. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9:418–427.

    Article  PubMed  CAS  Google Scholar 

  14. Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting longterm clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(8 suppl):5–26.

    Article  Google Scholar 

  15. Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(suppl 1):S27–S40.

    Article  PubMed  Google Scholar 

  16. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia. 2002;45:S23–S28.

    Article  PubMed  CAS  Google Scholar 

  17. Liebl A, Neiss A, Spannheimer A, et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany-results from the CODE-2 study. Exp Clin Endocrinol Diabetes. 2002;110:10–16.

    Article  PubMed  CAS  Google Scholar 

  18. Koster I, von FL, Ihle P, Schubert I, Hauner H. The cost burden of diabetes mellitus: the evidence from Germany-the CoDiM study. Diabetologia. 2006;49:1498–1504.

    Article  PubMed  CAS  Google Scholar 

  19. Neeser K, Lubben G, Siebert U, Schramm W. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. Pharmacoeconomics. 2004;22:321–341.

    Article  PubMed  Google Scholar 

  20. Banz K, Dinkel R, Hanefeld M, Schwanebeck U. Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus. A decisionanalytical approach. Pharmacoeconomics. 1998;13:449–459.

    Article  PubMed  CAS  Google Scholar 

  21. Szucs TD, Smala A, Fischer T. Costs of intensive insulin therapy in type 1 diabetes mellitus: experiences from the DCCT study [in German]. Fortschr Med. 1998;116:34–38.

    PubMed  CAS  Google Scholar 

  22. Statistisches Bundesamt Deutschland. Preisindizes für die Lebenshaltung. Gesundheitsbericht fur Deutschland. Statistisches Bundesamt Deutschland 19982005 (7.8) (Stuttgart: Metzler Poeschel; 1998:410–413). Available at: www. statistisches-bundesamt.de

    Google Scholar 

  23. Krankenhausdiagnosestatistik: diagnosedaten der krankenhauspatienten von 1997. Wiesbaden: Statistisches Bundesamt Deutchland; 1999.

  24. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Ritz E. Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension [in German]. Dtsch Med Wochenschr. 2004;129:13–18.

    Article  PubMed  CAS  Google Scholar 

  25. Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). Eur Heart J. 2001;22:1021–1031.

  26. Rychlik R, Pfiel T, Daniel D, Habs M, Klapper H. Socioeconomic relevance of treatment of chronic heart failure stage NYHA 2 with crataegus extract WS 1442 — a prospective 3-year pharmacoeconomic study. Value Health. 2004;7:695.

    Google Scholar 

  27. Laaser U, Breckenkamp J, Niermann U. Cost-effectiveness analysis of medical interventions in patients with stroke in Germany under special consideration of “stroke units”. Gesundh Okon Qual Manag. 1999;4:176–183.

    Google Scholar 

  28. Statistisches Bundesamt Deutschland. Preisindizes für die Lebenshaltung. Gesundheitsbericht fur Deutschland. Statistisches Bundesamt Deutschland 20051998 (5.23) (Stuttgart: Metzler Poeschel; 1998:254–258). Available at: www.statistisches-bundesamt.de

    Google Scholar 

  29. Schadlich PK, Brecht JG, Brunetti M, Pagano E, Rangoonwala B, Huppertz E. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy In Nephropathy (REIN) study for Germany from the perspective of statutory health insurance. Pharmacoeconomics. 2001;19:497–512.

    Article  PubMed  CAS  Google Scholar 

  30. Köhler A. Kölner Kommentar zum EBM 2002. Kölné: Deutscher Ärzte-Verlag; 2001.

    Google Scholar 

  31. Kelm-Kahl I, Ohrloff C. Minimal invasive chirurgie beim grauen star: was zahlt die kassee — medizin and gesdunheit [1.10.2001]; 2001. Available at: http://www3.lifeline.de/yavivo/

  32. Ghatnekar O. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four different European countries. J Wound Care. 2002;11:70.

    PubMed  CAS  Google Scholar 

  33. Dahmen HG. Diabetic foot syndrome and its risks: amputation, handicap, high-cost sequelae [in German]. Gesundheitswesen. 1997;59:566–568.

    PubMed  CAS  Google Scholar 

  34. Tarn T, Smith M. Pharmacoeconomic guidelines around the world. ISPOR Connections. 2004;10:5–15.

    Google Scholar 

  35. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997;6:327–340.

    Article  PubMed  CAS  Google Scholar 

  36. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56–64.

    Article  PubMed  CAS  Google Scholar 

  37. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diab Res Clin Pract. 2004;66:193–201.

    Article  CAS  Google Scholar 

  38. Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med. 2007;24:635–642.

    Article  PubMed  CAS  Google Scholar 

  39. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614–1620.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. IMS Health Economics and Outcomes Research, Gewerbestrasse 25, 4123 Allschwil, Basel, Switzerland

    William J. Valentine & Gordon Goodall

  2. Novo Nordisk A/S, Bagsværd, Denmark

    Mark Aagren & Steffen Nielsen

  3. IMS Health Economics and Outcomes Research, Basel, Switzerland

    Andrew J. Palmer & Katrina Erny-Albrecht

Authors
  1. William J. Valentine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gordon Goodall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark Aagren
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steffen Nielsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrew J. Palmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katrina Erny-Albrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Valentine, W.J., Goodall, G., Aagren, M. et al. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Adv Therapy 25, 567–584 (2008). https://doi.org/10.1007/s12325-008-0069-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-008-0069-z

Keywords

Search

Navigation